Alglucosidase alfa is named as a drug or biological intervention in 2 clinical trials in our UK and USA trial registers, 1 of which is recruiting. Lead sponsors include Genzyme, a Sanofi Company (1) and Amicus Therapeutics (1). Registered phases: Phase 2 and Observational. Conditions studied include Glycogen Storage Disease Type II-Pompe's Disease; Pompe Disease.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06121011 | A Global Prospective Observational Registry of Patients With Pompe Disease (ClinicalTrials.gov ↗) Pompe Disease |
Observational | Recruiting |
| NCT03019406 | A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa Glycogen Storage Disease Type II-Pompe's Disease |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Glycogen Storage Disease Type II-Pompe's Disease | 1 |
| Pompe Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| Genzyme, a Sanofi Company | 1 |
| Amicus Therapeutics | 1 |
| Register | Alglucosidase alfa trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Alglucosidase alfa works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Alglucosidase alfa (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.